- Also known as
- SLU PP 332 · SLU-PP 332 · SLUPP332 · pan-ERR agonist SLU-PP-332
- Class
- Synthetic pan-ERR (ERRα/β/γ) agonist, small molecule
- Form
- Lyophilised powder, as 5 mg vials and capsules
- Sizes
- 5 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C once in solution; stability in solution is not reported in these records
- BAC water per size
- 5 mg: 2 mL
- Molecular weight
- 290.3 g/mol (C18H14N2O2)
What is SLU-PP-332?
In the literature SLU-PP-332 is characterised as a synthetic pan-ERR (ERRα/β/γ) agonist, small molecule. Its molecular weight is 290.3 g/mol (C18H14N2O2). Several names across the literature all denote the same material, among them SLU PP 332, SLU-PP 332 and SLUPP332. Its sequence is recorded as Not a peptide: a small-molecule hydrazone, (E)-4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide. The work published on it is in mouse, in vitro and cell culture. There is no published human study of SLU-PP-332, so nothing on this page describes what it does in a person. Borealis Peptides provides it as lyophilised powder in 5 mg vials and capsules for in-vitro laboratory research. None of this is a medicine; it is not for human or veterinary use.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Billon C et al.2024 · J Pharmacol Exp Ther · PMID 37739806 | Mouse, diet-induced obese and ob/ob models of obesity and metabolic syndrome | Not stated in the abstract | Not stated in the abstract | SLU-PP-332 increased energy expenditure and fatty acid oxidation and decreased fat mass accumulation. It reduced obesity and improved insulin sensitivity in the metabolic syndrome models. |
| Xu W et al.2024 · Circulation · PMID 37961903 | Mouse, pressure overload-induced heart failure; cardiomyocyte cell work in vitro | Not stated in the abstract | 6-week pressure overload (treatment length not stated in the abstract) | SLU-PP-332 and SLU-PP-915 improved ejection fraction, reduced fibrosis and increased survival without affecting cardiac hypertrophy. They activated fatty acid and mitochondrial genes, and genetic dependency experiments showed ERRγ as the main mediator. |
| Okda HE et al.2026 · Int J Biol Macromol · PMID 41850449 | Cell culture, cell-based functional assays with computational modelling (structure-activity study) | Not stated in the abstract | Not stated in the abstract | The first full structure-activity analysis of the SLU-PP-332 scaffold identified the structural features that control ERRα and ERRγ agonism. Several analogues matched it with better ligand efficiency, solubility or metabolic stability, and SLU-PP-332 remained a benchmark for ERR activation. |
| Avliyakulov NK et al.2026 · Drug Test Anal · PMID 41688415 | In vitro, pooled human liver S9 fractions (metabolite identification) | Not stated in the abstract | Not stated in the abstract | 22 Phase I and II metabolites were identified by LC-MS/HRMS, including hydroxylated, glucuronidated and sulfated forms. Eight of them were the most abundant and potentially useful for doping control. |
| Möller T et al.2026 · Rapid Commun Mass Spectrom · PMID 41588687 | In vitro, human liver S9 fraction and human liver microsomes (analytical characterisation) | Not stated in the abstract | Not stated in the abstract | Nine metabolites were identified for SLU-PP-332: six Phase I metabolites and three Phase II conjugates. The authors describe the data as a basis for detecting its misuse as a performance-enhancing substance. |
What these studies don't show: None of this evidence came from a person. Nothing here backs a claim about human effects, and none is made. An effect in culture or in a mouse marks a starting point for research, not a conclusion about people. Confirming that the vial contains what the label states tells you nothing about whether the compound has any effect.
Every study links to its PubMed record. See all SLU-PP-332 studies in the research library →
SLU-PP-332 price in Canada: 5mg vial
Buy SLU-PP-332 in Canada in a 5mg vial, plus capsules and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 5 mg | $71.00 | $14.20/mg |
Other formats and kits
Is SLU-PP-332 available in Canada?
SLU-PP-332 carries no Drug Identification Number, which is the mark Health Canada gives a drug it has authorized. Its safety, efficacy and quality have not been assessed by any regulator in Canada. It is here strictly as research material for the lab, not for use in a person or an animal. How Health Canada treats research peptides →
Side effects reported in studies
A missing reported effect in a small study is no evidence of safety. Every statement here is linked to the study that reported it. None of the cited abstracts gives a tolerability finding for SLU-PP-332. Read more →
Doses used in studies
SLU-PP-332 FAQ
What is SLU-PP-332?
SLU-PP-332 is a synthetic pan-ERR (ERRα/β/γ) agonist, small molecule, and that classification is the point from which its published record begins. Its published work is in mouse, in vitro and cell culture. Borealis Peptides provides it as lyophilised powder in 5 mg vials and capsules for in-vitro laboratory research. It is neither a medicine nor meant for use in humans or animals. The table on this page lays out each study with its model and the result it reported.
Where can I buy SLU-PP-332 in Canada?
Borealis Peptides ships SLU-PP-332 from Canadian stock to research and business addresses within Canada. It is kept in 5 mg vials. Each batch is HPLC tested, and the certificate names the batch in your vial. Orders are taken for laboratory research only.
Is SLU-PP-332 legal in Canada?
SLU-PP-332 carries no Drug Identification Number, which is the mark Health Canada gives a drug it has authorized. Its safety, efficacy and quality have not been assessed by any regulator in Canada. This is laboratory research material in our hands, not for use in a person or an animal. Because Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, we take it as a label on intended supply rather than permission to use the material.
How much SLU-PP-332 should I use?
We will not answer dosing questions. SLU-PP-332 is not provided for use in a person or an animal, so there is no dose to describe. What this page carries is the amount each cited study used and the model it was used in, reproduced as the authors published it.
Has SLU-PP-332 been tested in people?
No. The 5 studies cited here used animals or cell culture. No published human study of SLU-PP-332 exists, so there is no evidence about what it does in a person, and this page makes no claim about that. The animal work is listed with its model so it can be read for what it is.
What storage does SLU-PP-332 need?
Keep sealed vials at −20 °C, dry and shielded from light. In solution it is kept at 2–8 °C once in solution; stability in solution is not reported in these records. Room-temperature transit does the dry powder no harm, and it should be refrigerated once received. Light and repeated warming cause more harm than the journey does.
Does SLU-PP-332 need bacteriostatic water?
The capsules are a dry oral format and take no liquid. Only the lyophilised vial ships dry, and that is the single format for which bacteriostatic water is relevant. It is sold separately. Each batch is run on HPLC, and the certificate you receive is for the batch that was sent to you.
How is the purity of SLU-PP-332 confirmed?
Identity and purity are verified by HPLC for every batch rather than once per product. The certificate states which batch it covers, and that batch number is printed on the vial, so any result can be traced back to the exact material behind it. Send us your order number and we forward it.
How does SLU-PP-332 compare with MOTS-C and 5-Amino-1MQ?
They are distinct compounds with distinct literatures, and no ranking is offered here. MOTS-C and 5-Amino-1MQ have 7 cited studies and 7 cited studies on their page against 5 here. Place the two evidence tables side by side and the difference shows directly.








